Statements (13)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
4
|
| gptkbp:bfsParent |
gptkb:Mirati_Therapeutics
|
| gptkbp:activities |
inhibitor of KRAS G12 C
|
| gptkbp:developed_by |
gptkb:Mirati_Therapeutics
|
| gptkbp:effective_date |
FDA approved
|
| https://www.w3.org/2000/01/rdf-schema#label |
Adagrasib
|
| gptkbp:ingredients |
C22 H24 Cl N5 O2 S
|
| gptkbp:is_tested_for |
clinical trials
|
| gptkbp:is_used_for |
treatment of cancer
|
| gptkbp:manager |
oral
|
| gptkbp:targets |
KRAS G12 C mutation
|
| gptkbp:weight |
445.98 g/mol
|